Background. In the USA, extended-spectrum β-lactamases (ESBLs) are implicated in an estimated 26,000 infections resulting in 1700 deaths annually. Ceftolozane/tazobactam (C/T) is a novel antibacterial active against most ESBL-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. C/T was studied in Phase 3 trials in patients with complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI). Data from these studies were evaluated to describe the characteristics and outcomes of patients infected with ESBL-producing Enterobacteriaceae.
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Methods. All trials were randomized and double-blind. In cUTI, treatment consisted of 7 days of intravenous C/T or levofloxacin, and in cIAI, 4-14 days of C/T plus metronidazole or meropenem. A baseline culture was obtained in both indications. Enterobacteriaceae were selected for ESBL characterization based on predefined criteria. Clinical and microbiological outcomes were determined 7 days post-treatment and 26-30 days after initiation of treatment in the cUTI and cIAI studies, respectively.
Results. A total of 150 patients (11%) had an ESBL-producing Enterobacteriaceae (genotypically verified) in the microbiologically evaluable population. Although most baseline characteristics were similar to the overall population, a greater proportion of patients with ESBLs were ≥65 years of age (31% vs 21%) or renally impaired (40% vs 31%) as compared with the overall population. Clinical cure rates for patients with ESBLs were 97% and 85% for the C/T arm and combined comparators, respectively. Microbiological eradication was achieved in 81% and 61% of patients in the C/T and comparator arms, respectively. At a breakpoint of 8 mg/L, 90% of ESBL-producing Enterobacteriaceae were susceptible to C/T; in the cUTI trials approximately 20% were susceptible to levofloxacin, and in the cIAI trials meropenem resistance was low (<5%).
Conclusion. Ceftolozane/tazobactam achieved high clinical and microbiological cure rates in cUTI and cIAI patients with ESBL infections. This was particularly notable, as patients with ESBLs were more likely to be elderly and/or renally impaired. C/T provides an empiric treatment option for infections caused by ESBL-producing pathogens.
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